Wedbush Raises Zions Bancorporation, National Association (NASDAQ:ZION) Price Target to $52.00

Zions Bancorporation, National Association (NASDAQ:ZION) had its price objective raised by Wedbush from $46.00 to $52.00 in a research report report published on Tuesday, Benzinga reports. The brokerage currently has a neutral rating on the bank’s stock. Wedbush also issued estimates for Zions Bancorporation, National Association’s Q2 2025 earnings at $1.12 EPS, Q3 2025 earnings at $1.23 EPS, Q4 2025 earnings at $1.26 EPS and FY2025 earnings at $4.60 EPS.

ZION has been the subject of a number of other research reports. Stephens raised their price objective on Zions Bancorporation, National Association from $48.00 to $51.00 and gave the company an equal weight rating in a research report on Tuesday. StockNews.com upgraded shares of Zions Bancorporation, National Association from a sell rating to a hold rating in a research report on Wednesday, July 17th. Wells Fargo & Company raised their price objective on Zions Bancorporation, National Association from $44.00 to $52.00 and gave the company an equal weight rating in a research note on Tuesday. Robert W. Baird lifted their price objective on shares of Zions Bancorporation, National Association from $50.00 to $52.00 and gave the stock a neutral rating in a research note on Tuesday. Finally, The Goldman Sachs Group lifted their price target on shares of Zions Bancorporation, National Association from $47.00 to $54.00 and gave the stock a neutral rating in a research note on Tuesday. Two investment analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of Hold and an average target price of $48.06.

Zions Bancorporation, National Association Price Performance

NASDAQ ZION opened at $51.80 on Tuesday. The stock has a market cap of $7.65 billion, a price-to-earnings ratio of 13.02, a PEG ratio of 5.36 and a beta of 1.11. Zions Bancorporation, National Association has a 12 month low of $28.90 and a 12 month high of $53.32. The company’s 50 day moving average is $44.04 and its two-hundred day moving average is $42.41. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 1.01.

Zions Bancorporation, National Association (NASDAQ:ZION) last issued its earnings results on Monday, July 22nd. The bank reported $1.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.18. Zions Bancorporation, National Association had a return on equity of 14.13% and a net margin of 13.53%. The company had revenue of $776.00 million for the quarter, compared to the consensus estimate of $761.61 million. During the same quarter last year, the company earned $1.11 EPS. The firm’s quarterly revenue was down .5% on a year-over-year basis. As a group, research analysts anticipate that Zions Bancorporation, National Association will post 4.36 earnings per share for the current year.

Insiders Place Their Bets

In other Zions Bancorporation, National Association news, EVP Rebecca K. Robinson sold 5,291 shares of the company’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $43.66, for a total transaction of $231,005.06. Following the completion of the sale, the executive vice president now owns 22,238 shares in the company, valued at $970,911.08. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, EVP Rebecca K. Robinson sold 5,291 shares of the firm’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $43.66, for a total value of $231,005.06. Following the sale, the executive vice president now directly owns 22,238 shares in the company, valued at approximately $970,911.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Alan M. Forney sold 1,500 shares of the firm’s stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $43.68, for a total transaction of $65,520.00. Following the completion of the sale, the chief executive officer now owns 22,181 shares of the company’s stock, valued at $968,866.08. The disclosure for this sale can be found here. Insiders have sold a total of 7,296 shares of company stock worth $319,192 in the last three months. Corporate insiders own 2.22% of the company’s stock.

Institutional Investors Weigh In On Zions Bancorporation, National Association

Institutional investors have recently added to or reduced their stakes in the business. Fidelis Capital Partners LLC acquired a new position in Zions Bancorporation, National Association during the 1st quarter valued at approximately $27,000. Federated Hermes Inc. increased its holdings in Zions Bancorporation, National Association by 105.4% in the 4th quarter. Federated Hermes Inc. now owns 645 shares of the bank’s stock worth $28,000 after buying an additional 331 shares during the period. Jones Financial Companies Lllp purchased a new stake in shares of Zions Bancorporation, National Association in the 4th quarter valued at $29,000. ORG Partners LLC acquired a new position in Zions Bancorporation, National Association during the second quarter valued at $33,000. Finally, Quarry LP purchased a new position in shares of Zions Bancorporation, National Association during the 4th quarter valued at about $49,000. Institutional investors and hedge funds own 76.84% of the company’s stock.

Zions Bancorporation, National Association Company Profile

Zions Bancorporation, National Association provides various banking products and related services primarily in the states of Arizona, California, Colorado, Idaho, Nevada, New Mexico, Oregon, Texas, Utah, Washington, and Wyoming. It operates through Zions Bank, California Bank & Trust, Amegy Bank, National Bank of Arizona, Nevada State Bank, Vectra Bank Colorado, and The Commerce Bank of Washington segments.